TY  - JOUR
AU  - Brogan, Paul A
AU  - Hofer, Michael
AU  - Kuemmerle-Deschner, Jasmin B
AU  - Koné-Paut, Isabelle
AU  - Roesler, Joachim
AU  - Kallinich, Tilmann
AU  - Horneff, Gerd
AU  - Calvo Penadés, Inmaculada
AU  - Sevilla-Perez, Belén
AU  - Goffin, Laurence
AU  - Lauwerys, Bernard R
AU  - Lachmann, Helen J
AU  - Uziel, Yosef
AU  - Wei, Xiaoling
AU  - Laxer, Ronald M
PY  - 2019
DO  - 10.1002/art.41004
UR  - http://hdl.handle.net/10668/14073
T2  - Arthritis & rheumatology (Hoboken, N.J.)
AB  - To assess long-term efficacy and safety of canakinumab and the response to vaccination in children ages ≤5 years with cryopyrin-associated periodic syndrome (CAPS). CAPS patients (ages ≤5 years) received 2 mg/kg canakinumab subcutaneously every 8...
LA  - en
KW  - Antibodies, Monoclonal, Humanized
KW  - Antibody Formation
KW  - C-Reactive Protein
KW  - Child, Preschool
KW  - Cryopyrin-Associated Periodic Syndromes
KW  - Diarrhea
KW  - Female
KW  - Fever
KW  - Humans
KW  - Infant
KW  - Infant, Newborn
KW  - Male
KW  - Nasopharyngitis
KW  - Respiratory Tract Infections
KW  - Serum Amyloid A Protein
KW  - Treatment Outcome
KW  - Vaccines
TI  - Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger.
TY  - research article
VL  - 71
ER  -